Interpreting the clinical significance of multiple large-scale mitochondrial DNA deletions (MLSMD) in skeletal muscle tissue in the diagnostic evaluation of primary mitochondrial d... by Jing Wang, Jing Wang, James T. Peterson, Joaquim Diego D. Santos, Ada J. S. Chan, Maria Alejandra Diaz-Miranda, Imon Rahaman, Jean Flickinger, Amy Goldstein, Amy Goldstein, Emily Bogush, Elizabeth M. McCormick, Colleen C. Muraresku, Vernon E. Anderson, Matthew C. Dulik, Matthew C. Dulik, Douglas C. Wallace, Douglas C. Wallace, Rui Xiao, Marni J. Falk, Marni J. Falk, Angela N. Viaene, Angela N. Viaene, Zarazuela Zolkipli-Cunningham, Zarazuela Zolkipli-Cunningham, Zarazuela Zolkipli-Cunningham

Get full text

Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial by Amel Karaa, Enrico Bertini, Valerio Carelli, Bruce Cohen, Gregory M. Ennes, Marni J. Falk, Amy Goldstein, Gráinne Gorman, Richard Haas, Michio Hirano, Thomas Klopstock, Mary Kay Koenig, Cornelia Kornblum, Costanza Lamperti, Anna Lehman, Nicola Longo, Maria Judit Molnar, Sumit Parikh, Han Phan, Robert D. S. Pitceathly, Russekk Saneto, Fernando Scaglia, Serenella Servidei, Mark Tarnopolsky, Antonio Toscano, Johan L. K. Van Hove, John Vissing, Jerry Vockley, Jeffrey S. Finman, Anthony Abbruscato, David A. Brown, Alana Sullivan, James A. Shiffer, Michelango Mancuso, on behalf of the MMPOWER-3 Trial Investigators

Get full text